Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
RPRX [NASD]
Repros Therapeutics Inc.
Index- P/E- EPS (ttm)-1.32 Insider Own0.30% Shs Outstand23.11M Perf Week3.01%
Market Cap150.22M Forward P/E- EPS next Y-1.52 Insider Trans6.12% Shs Float23.01M Perf Month-27.46%
Income-30.40M PEG- EPS next Q-0.39 Inst Own90.20% Short Float15.24% Perf Quarter-53.54%
Sales- P/S- EPS this Y-12.70% Inst Trans-4.98% Short Ratio2.97 Perf Half Y-60.98%
Book/sh2.61 P/B2.49 EPS next Y0.00% ROA-40.40% Target Price28.33 Perf Year-63.63%
Cash/sh2.63 P/C2.47 EPS next 5Y- ROE-42.50% 52W Range5.92 - 22.57 Perf YTD-64.48%
Dividend- P/FCF- EPS past 5Y29.30% ROI- 52W High-71.20% Beta1.14
Dividend %- Quick Ratio14.90 Sales past 5Y- Gross Margin- 52W Low9.80% ATR1.06
Employees28 Current Ratio14.90 Sales Q/Q- Oper. Margin- RSI (14)30.33 Volatility9.83% 9.07%
OptionableYes Debt/Eq0.00 EPS Q/Q0.00% Profit Margin- Rel Volume0.60 Prev Close6.22
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume1.18M Price6.50
Recom1.70 SMA20-27.95% SMA50-48.38% SMA200-59.47% Volume703,746 Change4.50%
14-May-13Reiterated Ascendiant Capital Markets Strong Buy $19 → $23
28-Mar-13Reiterated Ladenburg Thalmann Buy $18 → $25
15-Nov-12Reiterated Ascendiant Capital Markets Strong Buy $12 → $18
09-Oct-12Reiterated Ladenburg Thalmann Buy $15 → $18
10-Apr-12Initiated Ascendiant Capital Markets Strong Buy $6
16-Mar-11Reiterated Ladenburg Thalmann Buy $6 → $9
21-Oct-14 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
04:01PM  Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile GlobeNewswire
20-Oct-14 01:33PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX PR Newswire
10:36AM  INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
09:00AM  Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. PR Newswire
17-Oct-14 08:28PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm PR Newswire -39.96%
03:17PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX Business Wire
12:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX PR Newswire
09:26AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
09:15AM  Repros Therapeutics shares drop on drug application setback at MarketWatch
08:57AM  [$$] Repros Therapeutics Shares Drop Premarket at The Wall Street Journal
16-Oct-14 08:01PM  Upcoming FDA Meeting to be Type C Meeting GlobeNewswire
29-Sep-14 01:10PM  Can Repros Therapeutics Shares Still More Than Double? at 24/7 Wall St.
08:00AM  Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Zacks
26-Sep-14 02:16PM  5 Breakout Stocks Under $10 Set to Soar at TheStreet +16.96%
01:17PM  Nasdaq stocks posting largest percentage increases AP
08:43AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:45AM  FDA Schedules Type B Pre-NDA Meeting With Repros GlobeNewswire
25-Sep-14 08:20PM  Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism GlobeNewswire
22-Sep-14 04:37PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
02:13PM  Nasdaq stocks posting largest percentage decreases AP
10:14AM  [$$] FDA Recommendation Doesn't Apply to Androxal, Repros Says at The Wall Street Journal
09:15AM  Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury GlobeNewswire
18-Sep-14 01:04PM  Rite Aid Plunges As Full-Year Outlook Dims at TheStreet -21.66%
12:34PM  Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today at TheStreet
07:06AM  Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% Zacks
05-Sep-14 02:49PM  Infoblox Inc. (BLOX) Climbs On Earnings at TheStreet
12:36PM  Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline Benzinga
28-Aug-14 03:30PM  Repros Reports Encouraging Late-Stage Data on Androxal Zacks +18.51%
01:11PM  Williams-Sonoma Stumbles After Yesterday's Surge at TheStreet
11:15AM  Markets Open Lower; Dollar General Profit Matches Street View Benzinga
10:00AM  Why Repros Therapeutics (RPRX) Stock Is Surging Today at TheStreet
08:35AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
27-Aug-14 09:46PM  Repros says its testosterone drug found superior in study Reuters
08:10PM  Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism GlobeNewswire
22-Aug-14 06:47AM  Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% Zacks +11.76%
20-Aug-14 04:45PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
19-Aug-14 01:04PM  REPROS THERAPEUTICS INC. Financials EDGAR Online Financials
12-Aug-14 09:50AM  Repros Therapeutics Q2 Loss a Penny Wider than Expected Zacks
11-Aug-14 09:15AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
09:15AM  Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results GlobeNewswire
17-Jul-14 04:20PM  Repros Gets Additional FDA Guidance for Androxal Zacks
16-Jul-14 09:20AM  FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo GlobeNewswire
09:19AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
20-Jun-14 04:38PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo EDGAR Online
13-May-14 10:22AM  Repros Therapeutics reaches enrollment goal in second Androxal study at theflyonthewall.com
10:15AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
10:15AM  Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel GlobeNewswire
10:00AM  Repros' Q1 Loss In Line with Expectations Zacks
12-May-14 09:23AM  Repros Therapeutics reports Q1 EPS (37c), consensus (35c) at theflyonthewall.com
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
09:15AM  Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results GlobeNewswire
08-May-14 08:46AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online -5.48%
05-May-14 07:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX PR Newswire
30-Apr-14 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
04:01PM  FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel GlobeNewswire
15-Apr-14 06:05PM  Repros Completes Enrollment for Androxal Study Zacks
14-Apr-14 10:06AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events EDGAR Online
09:44AM  Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel GlobeNewswire
01-Apr-14 08:50AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
19-Mar-14 01:04PM  REPROS THERAPEUTICS INC. Financials EDGAR Online Financials
18-Mar-14 04:10PM  Repros Provides Proellex Update Zacks
17-Mar-14 09:21AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events EDGAR Online
09:20AM  Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis GlobeNewswire
14-Mar-14 10:33AM  REPROS THERAPEUTICS INC. Files SEC form 10-K, Annual Report EDGAR Online
08:50AM  Narrower-than-Expected Q4 Loss at Repros Zacks
13-Mar-14 09:15AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
09:15AM  Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results GlobeNewswire
11-Feb-14 05:27PM  Data on Repros' Androxal Zacks
10-Feb-14 03:13PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
09:15AM  Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism GlobeNewswire
07:21AM  Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% Zacks
07-Feb-14 09:27AM  Repros Shares Soar After FDA Meeting Zacks +6.14%
06-Feb-14 03:11PM  Why Repros Therapeutics, Inc. Shares Soared at Motley Fool +15.77%
11:59AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
11:35AM  Repros Therapeutics rises on Androxal update AP
12:22AM  Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism GlobeNewswire
21-Jan-14 10:20AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
16-Jan-14 08:15AM  Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential 24/7 Wall St.
05:44AM  Can the Rally in Repros Therapeutics (RPRX) Shares Continue? Zacks
15-Jan-14 08:00AM  Pre-Market Pulse: Dendreon, Novartis AG, Stryker, and Repros Therapeutics PR Newswire +6.85%
08-Jan-14 09:15AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events EDGAR Online
09:15AM  Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel GlobeNewswire
20-Dec-13 03:13PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase II clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Masterson Nola EDirectorSep 15Buy14.342002,8683,305Sep 17 09:43 AM
PODOLSKI JOSEPHPresident and CEOAug 14Buy13.912,10029,21161,045Aug 14 03:53 PM
Anderson KatherineChief Financial OfficerAug 14Buy13.852,00027,7008,375Aug 14 03:51 PM